SCHEMBL294824

SCHEMBL294824

CCCc1cc(F)cc(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.42
DAO P14920 2/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
CYP17A1 P05093 1/20 0.35
CYP21A2 P08686 1/20 0.35
CYP11B1 P15538 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA9 Q16790 1/20 0.35
PTGS2 P35354 2/20 0.34
CYP3A4 P08684 1/20 0.34
LPL P06858 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
TAAR1 Q96RJ0 2/20 0.34
PTGS1 P23219 1/20 0.34
NR3C1 P04150 1/20 0.34
PGR P06401 1/20 0.34
NR3C2 P08235 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL6194233 0.97 IDO1 (0.41) IDO1DAOCNR1CNR2TRPV1
SCHEMBL14473767 0.94 CNR1 (0.38) IDO1DAOCNR1CNR2TRPV1
SCHEMBL16958903 0.85 FFAR4 (0.39) IDO1CNR1CNR2PTGS2PTGS1
SCHEMBL8990727 0.85 CYP17A1 (0.56) CNR1CNR2CYP17A1CYP21A2CYP11B1
SCHEMBL28019926 0.85 IDO1 (0.38) IDO1DAOCNR1CNR2TRPV1
SCHEMBL4197444 0.84 NPC1 (0.50) IDO1TRPV1CA1PTGS2CYP3A4
SCHEMBL16955785 0.84 CYP4F2 (0.46) CNR1CNR2TRPV1PTGS2CYP3A4
SCHEMBL5411709 0.84 POLB (0.33) IDO1DAOCNR1CNR2TRPV1
SCHEMBL13349208 0.84 DAO (0.39) IDO1DAOCNR1CNR2CYP17A1
SCHEMBL16958901 0.84 CNR1 (0.32) IDO1DAOCNR1CNR2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119792995-A Extraction liquid for extracting lithium ion battery electrolyte and extraction method of lithium ion battery electrolyte 江苏正力新能电池技术股份有限公司 2025-04-11 CN claimed
CN-101768447-B Polyfluoric terphenyl liquid crystal compound and synthesis method and use thereof SHIJIAZHUANG YONGSHENG HUATSING LIQUID CRYSTAL CO LTD 2013-08-14 CN claimed
WO-2025092096-A1 COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 华为技术有限公司 2025-05-08 WO disclosed
CN-119912473-A Compound and preparation method and application thereof 华为技术有限公司 2025-05-02 CN disclosed
CN-119792995-A Extraction liquid for extracting lithium ion battery electrolyte and extraction method of lithium ion battery electrolyte 江苏正力新能电池技术股份有限公司 2025-04-11 CN disclosed
US-20240217963-A1 RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2024-07-04 US disclosed
US-20240004296-A1 RESIST UNDERLAYER FILM-FORMING COMPOSITION NISSAN CHEMICAL CORPORATION (JP) 2024-01-04 US disclosed
US-20230312587-A1 PTERIDINONE COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-10-05 US disclosed
US-20230303562-A1 PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-09-28 US disclosed
US-20230309388-A1 ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE Beijing Summer Sprout Technology Co., Ltd. (CN) 2023-09-28 US disclosed
CN-113874420-B Resin film and metal-clad laminate 日铁化学材料株式会社 2023-09-26 CN disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 US disclosed
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-07-12 US disclosed
US-20070032531-A1 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORPORATION (US) 2007-02-08 US disclosed
US-20070021331-A1 Methods of using macrocyclic modulators of the ghrelin receptor TRANZYME PHARMA INC. 2007-01-25 US disclosed
US-5800734-A 1-fluorocyclohexene-difluorophenyl derivatives ROLIC AG (CH) 1998-09-01 US disclosed
EP-0598354-B1 Fluor substituted tolan derivatives and liquid crystals mixtures containing them MERCK PATENT GMBH (DE) 1997-04-09 EP disclosed
US-5582767-A Fluorosubstituted tolane derivatives HOFFMANN-LA ROCHE INC. (US) 1996-12-10 US disclosed
EP-0736513-A1 1-Fluorcyclohexene-difluorphenyl derivatives F. HOFFMANN-LA ROCHE AG (CH) 1996-10-09 EP disclosed
EP-0598354-A1 Fluor substituted tolan derivatives and liquid crystals mixtures containing them F. HOFFMANN-LA ROCHE AG (CH) 1994-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303562-A1 PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP51A1, CYP4F11, WEE1 IDO1 1056/4885DAO 4312/4885CNR1 1874/4885
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 IDO1 4374/4885DAO 4682/4885CNR1 287/4885
US-20070032531-A1 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE SPHK1, SPHK2, S1PR2 IDO1 2639/4885DAO 3290/4885CNR1 1246/4885
US-20070191604-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 IDO1 2606/4885DAO 4108/4885CNR1 2910/4885
US-20230309388-A1 ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE OCIAD1, OCIAD2, SLCO4C1 IDO1 3050/4885DAO 2480/4885CNR1 3973/4885
US-20070021331-A1 Methods of using macrocyclic modulators of the ghrelin receptor GHSR, GHRHR, GIPR IDO1 3963/4885DAO 3976/4885CNR1 166/4885
US-20230312587-A1 PTERIDINONE COMPOUNDS AND USES THEREOF DPYD, PKD1, TYMP IDO1 952/4885DAO 1329/4885CNR1 2459/4885
US-20240217963-A1 RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF RIPK1, RIPK2, RIPK4 IDO1 3677/4885DAO 4484/4885CNR1 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.